HK1245770A1 - 尿嘧啶化合物的新型結晶 - Google Patents
尿嘧啶化合物的新型結晶Info
- Publication number
- HK1245770A1 HK1245770A1 HK18105025.8A HK18105025A HK1245770A1 HK 1245770 A1 HK1245770 A1 HK 1245770A1 HK 18105025 A HK18105025 A HK 18105025A HK 1245770 A1 HK1245770 A1 HK 1245770A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- novel crystal
- uracil compound
- uracil
- compound
- crystal
- Prior art date
Links
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 229940035893 uracil Drugs 0.000 title 1
- -1 uracil compound Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015093862 | 2015-05-01 | ||
| PCT/JP2016/063495 WO2016178416A1 (ja) | 2015-05-01 | 2016-04-28 | ウラシル化合物の新規結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1245770A1 true HK1245770A1 (zh) | 2018-08-31 |
Family
ID=57217651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18105025.8A HK1245770A1 (zh) | 2015-05-01 | 2018-04-18 | 尿嘧啶化合物的新型結晶 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10259792B2 (zh) |
| EP (1) | EP3290406A4 (zh) |
| JP (1) | JP6479970B2 (zh) |
| KR (2) | KR20200039846A (zh) |
| CN (1) | CN107531646B (zh) |
| AU (1) | AU2016258388B2 (zh) |
| BR (1) | BR112017023649A2 (zh) |
| CA (1) | CA2984724C (zh) |
| HK (1) | HK1245770A1 (zh) |
| MX (1) | MX2017013969A (zh) |
| MY (1) | MY185785A (zh) |
| PH (1) | PH12017501948A1 (zh) |
| RU (1) | RU2686722C1 (zh) |
| SG (1) | SG11201708613SA (zh) |
| WO (1) | WO2016178416A1 (zh) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6450323B2 (ja) | 2013-01-07 | 2019-01-09 | ユニバーシティ オブ サザン カリフォルニア | デオキシウリジントリホスファターゼ阻害剤 |
| WO2015103489A1 (en) | 2014-01-03 | 2015-07-09 | University Of Southern California | Heteroatom containing deoxyuridine triphosphatase inhibitors |
| WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| EP3319939A1 (en) | 2015-07-08 | 2018-05-16 | CV6 Therapeutics (NI) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US10544105B2 (en) | 2015-07-08 | 2020-01-28 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
| US10577321B2 (en) | 2015-07-08 | 2020-03-03 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| WO2018098209A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
| WO2018098206A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| WO2018098208A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
| WO2018098204A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
| US11014924B2 (en) | 2016-11-23 | 2021-05-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US11247984B2 (en) | 2017-01-05 | 2022-02-15 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2726579C (en) * | 2008-06-03 | 2015-02-17 | Taiho Pharmaceutical Co., Ltd. | Novel uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity |
| JP2013032293A (ja) * | 2009-11-30 | 2013-02-14 | Taiho Yakuhin Kogyo Kk | ヒトｄＵＴＰａｓｅ阻害活性を有する５−フルオロウラシル化合物又はその塩 |
| BR112012013049A2 (pt) | 2009-11-30 | 2016-11-22 | Taiho Pharmaceutical Co Ltd | potencializador do efeito antitumor. |
-
2016
- 2016-04-28 RU RU2017141732A patent/RU2686722C1/ru active
- 2016-04-28 BR BR112017023649-4A patent/BR112017023649A2/pt not_active Application Discontinuation
- 2016-04-28 KR KR1020207010240A patent/KR20200039846A/ko not_active Application Discontinuation
- 2016-04-28 MX MX2017013969A patent/MX2017013969A/es unknown
- 2016-04-28 CN CN201680025317.8A patent/CN107531646B/zh active Active
- 2016-04-28 MY MYPI2017704025A patent/MY185785A/en unknown
- 2016-04-28 US US15/570,779 patent/US10259792B2/en active Active
- 2016-04-28 AU AU2016258388A patent/AU2016258388B2/en active Active
- 2016-04-28 CA CA2984724A patent/CA2984724C/en active Active
- 2016-04-28 EP EP16789552.3A patent/EP3290406A4/en not_active Withdrawn
- 2016-04-28 JP JP2017516609A patent/JP6479970B2/ja active Active
- 2016-04-28 KR KR1020177033388A patent/KR20170137916A/ko active Application Filing
- 2016-04-28 SG SG11201708613SA patent/SG11201708613SA/en unknown
- 2016-04-28 WO PCT/JP2016/063495 patent/WO2016178416A1/ja active Application Filing
-
2017
- 2017-10-25 PH PH12017501948A patent/PH12017501948A1/en unknown
-
2018
- 2018-04-18 HK HK18105025.8A patent/HK1245770A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10259792B2 (en) | 2019-04-16 |
| CA2984724A1 (en) | 2016-11-10 |
| CA2984724C (en) | 2020-06-02 |
| BR112017023649A2 (pt) | 2018-07-17 |
| WO2016178416A1 (ja) | 2016-11-10 |
| KR20200039846A (ko) | 2020-04-16 |
| EP3290406A1 (en) | 2018-03-07 |
| US20180134666A1 (en) | 2018-05-17 |
| AU2016258388B2 (en) | 2019-03-28 |
| EP3290406A4 (en) | 2018-11-14 |
| CN107531646A (zh) | 2018-01-02 |
| SG11201708613SA (en) | 2017-11-29 |
| MY185785A (en) | 2021-06-08 |
| CN107531646B (zh) | 2020-11-03 |
| RU2686722C1 (ru) | 2019-04-30 |
| AU2016258388A1 (en) | 2017-11-23 |
| MX2017013969A (es) | 2018-02-21 |
| JPWO2016178416A1 (ja) | 2017-10-26 |
| JP6479970B2 (ja) | 2019-03-06 |
| PH12017501948A1 (en) | 2018-03-19 |
| KR20170137916A (ko) | 2017-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1255921A1 (zh) | 嘧啶化合物 | |
| HK1245770A1 (zh) | 尿嘧啶化合物的新型結晶 | |
| IL255817A (en) | Synthesis of heterocyclic compounds | |
| GB2542881B (en) | Crystal forms of ß-nicotinamide mononucleotide | |
| IL250022A0 (en) | New converted pyrimidine compounds | |
| SI3380554T2 (sl) | Kristalne oblike per-kloro-gama-ciklodekstrinov | |
| SG11201708793SA (en) | Crystals of azabicyclic compound | |
| HK1244274A1 (zh) | C21h22ci2n4o2的晶型 | |
| HK1250719A1 (zh) | 脫氧糖胺的合成 | |
| PL3113773T3 (pl) | Krystaliczne postaci grapiprantu | |
| IL253479A0 (en) | Crystalline forms of efinconazole | |
| AP2016009506A0 (en) | Pyrimidine compound | |
| EP3207034A4 (en) | Anhydrous crystalline form of s-equol | |
| IL270961A (en) | Crystalline form of N-butyldeoxygalactonogirimycin | |
| PL3247687T3 (pl) | Zastosowanie masy wyrównującej | |
| PT3424930T (pt) | Cristal de um composto com atividade inibidora de jak | |
| SG11201704431VA (en) | Novel salt of fused pyrimidine compound and crystal thereof | |
| PT3395819T (pt) | Forma cristalina de derivado de aminopirano substituído | |
| HK1247921A1 (zh) | 哌嗪化合物的新晶體 | |
| IL270937A (en) | Crystalline forms of saltalicib |